Chimerix

2012

Chimerix to Present at Upcoming Needham and Future Leaders Conferences    

RESEARCH TRIANGLE PARK, NC, April 3, 2012 – Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced presentations at two upcoming investor conferences in New York City. Timothy W. Trost, Chief Financial Officer, will present at the Needham… > Read More

Chimerix to Present at Cowen and Company's 32nd Annual Health Care Conference    

RESEARCH TRIANGLE PARK, NC, March 5, 2012 – Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced that Kenneth I. Moch, President and Chief Executive Officer, will present at Cowen and Company's 32nd Annual Health Care Conference on… > Read More

Chimerix Antiviral Compound CMX001 Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients    

- Positive Phase 2 Study Results Presented in 'Best Abstracts' Oral Session at the 2012 BMT Tandem Meetings

Research Triangle Park, NC, February 6, 2012 – Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics,… > Read More

Chimerix Announces Presentation of Final Data from CMX001 Ph 2 Trial in Prophylaxis of CMV in Hematopoietic Stem Cell Transplant Patients    

- Abstract Receives "BEST ABSTRACTS AWARD FOR CLINICAL RESEARCH" at 2012 BMT Tandem Meetings on February 3rd, 2012

RESEARCH TRIANGLE PARK, NC, January 25, 2012 – Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics,… > Read More